Satellos Bioscience to Participate in PPMD's Annual Conference in Las Vegas
Article content
TORONTO — Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (' Satellos ' or the ' Company '), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced its participation in the 2025 Parent Project Muscular Dystrophy (PPMD) Annual Conference, taking place June 19–21 in Las Vegas, Nevada.
Article content
The PPMD Annual Conference brings together families, researchers, clinicians, and companies committed to improving outcomes for people living with Duchenne. Satellos will be onsite to engage with the Duchenne community, listen to families' experiences, and share updates on its science and mission to regenerate muscle from within.
Article content
Article content
'We're looking forward to connecting in person with families and advocates who are at the heart of this work,' said Frank Gleeson, Co-founder and CEO of Satellos. 'This conference is a powerful reminder of why we're focused on developing a new approach to treat Duchenne — one that aims to restore the body's ability to repair muscle.'
Article content
Attendees can meet members of the Satellos team throughout the event and learn more by visiting the company's booth in the exhibition hall.
Article content
About Satellos Bioscience Inc.
Article content
Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that Satellos has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. By restoring this missing dystrophin signal in DMD, SAT-3247 enables muscle stem cells to divide properly and more efficiently, promoting natural muscle repair and regeneration. SAT-3247 is currently in clinical development as a potential disease-modifying treatment initially for DMD. Satellos also is leveraging its proprietary discovery platform MyoReGenX™ to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. For more information, visit www.satellos.com.
Article content
This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Satellos and its business, which may include, but are not limited to, statements regarding the potential for SAT-3247 to represent a disease modifying approach to the therapeutic treatment of people living with Duchenne; anticipated benefits to patients from a small molecule treatment for Duchenne; the advancement SAT-3247 through clinical trials; the pharmacodynamic properties and mechanism-of-action of SAT-3247; the potential of our approach in other degenerative muscle diseases; its/their prospective impact on Duchenne patients, patients with other degenerative muscle disease or muscle injury or trauma, and on muscle regeneration generally; and Satellos' technologies and drug development plans. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, occurrences or developments, are 'forward-looking information or statements.' Often but not always, forward-looking information or statements can be identified by the use of words such as 'shall', 'intends', 'believe', 'plan', 'expect', 'intend', 'estimate', 'anticipate', 'potential', 'prospective' , 'assert' or any variations (including negative or plural variations) of such words and phrases, or state that certain actions, events or results 'may', 'might', 'can', 'could', 'would' or 'will' be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, risks relating to the pharmaceutical and bioscience industry (including the risks associated with preclinical and clinical trials and regulatory approvals), and the research and development of therapeutics, the results of preclinical and clinical trials, general market conditions and equity markets, economic factors and management's ability to manage and to operate the business of the Company generally, including inflation and the costs of operating a biopharma business, and those risks listed in the 'Risk Factors' section of Satellos' Annual Information Form dated March 26, 2025 (which is located on Satellos' profile at www.sedarplus.ca). Although Satellos has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Satellos does not undertake any obligation to publicly update or revise any forward-looking statement, whether resulting from new information, future events, or otherwise.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Investors:
Article content
Liz Williams, CFO,
Article content
ir@satellos.com
Article content
Article content
Media:
Article content
Emily Williams, Senior Director, Communications,
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
39 minutes ago
- CTV News
IWK launches African Nova Scotian Service to provide ‘culturally responsive care'
The IWK Health Centre in Halifax has launched a new program designed to provide mental health and addiction services to African Nova Scotian children, youth and their families who have ties to one of the province's 52 historic Black communities. The African Nova Scotian Service (ANSS) at the children's hospital will support historical African Nova Scotian children and youth up to their 19th birthday. The program will include services such as: individual and family mental health and addiction support educational programs treatment groups community outreach and resource navigation 'This initiative addresses the long-standing underrepresentation of African Nova Scotian families within traditional health care systems and aims to deliver care that honours the unique cultural context of the community,' reads a news release from the IWK Health Centre. The program will be supported by an interprofessional group of clinicians that includes social workers, nurses, occupational therapists and recreational therapists, 'all of whom are of African Nova Scotian ancestry with deep roots in the community.' 'The official launch of the IWK African Nova Scotian Service is a historical milestone for IWK and the African Nova Scotian (ANS) community and I am so proud to be a part of this journey,' says Cynthia Jordan, ANSS Clinical Team Lead. 'Providing culturally responsive care is about integrating evidence-based programs and delivering service with a lens that honours ANS culture, strength, resiliency, values, and beliefs. The IWK ANSS team is committed to building trusting relationships within the historical ANS community it serves.' Nova Scotians who would like to access IWK ANSS can call Central Referral toll-free at 1-855-922-1122. According to the release, calls will take between 20 and 30 minutes and an Access Navigator will collect your information and connect you to the appropriate services. Nova Scotians can request ANSS support at the time of first contact or at any point during service. 'I was so happy to learn the IWK now has a service that prioritizes the needs of historical African Nova Scotian children, youth, and their families,' says former IWK patient, Janelle Oliver-Harris. 'African Nova Scotians will have the opportunity to see someone that not only looks like them but understands and provides service in a way that honours their diverse needs. Since receiving services at IWK, I experienced having a Black clinician and I know the benefits of having diversity reflected in mental health services. Having this service and team will make a difference.' For more Nova Scotia news, visit our dedicated provincial page
CTV News
an hour ago
- CTV News
Barrie apartment rentals make top 10 list of most expensive in Canada: report
The City of Barrie made the top 10 list of the most expensive cities to rent in Canada, according to a new report. ranked Barrie as the 9th most expensive city to rent in the nation last month with the prices of one and two-bedrooms settling at medians of $1,800 and $2,000, respectively. The report states the average monthly rent in Barrie is up overall by 1.02 per cent compared to last month, but is down 12.11 per cent year-over-year. Vancouver, B.C. remains the most expensive city in Canada to rent a one-bedroom, holding steady at $2,520 on average. Despite a slight decrease in one-bedroom rental prices by 1.3 per cent, Toronto maintained its position in third place, with rent for a one-bedroom at $2,260. Also making the top 10 are Burnaby, B.C., Victoria, B.C., Halifax, N.S., Ottawa, Kelowna, B.C., Kitchener, and Oshawa. "This marks the first time in five months that the national rents have posted gains across the board, both monthly and annually," reports. "This turnaround signals a shift in market momentum as we enter peak moving season, a period that typically brings heightened demand and competition. With more renters actively searching and relocating during the warmer months, we're starting to see upward pressure return to the national rates." analyzes rental data from active listings nationwide based on a monthly basis.
Globe and Mail
an hour ago
- Globe and Mail
Reeflex Solutions Inc. Announces Credit Facility With the Royal Bank of Canada
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, June 16, 2025 (GLOBE NEWSWIRE) -- Reeflex Solutions Inc. (TSXV: RFX) (' Reeflex ' or the ' Company ') is pleased to announce that it has entered into a credit agreement with the Royal Bank of Canada (' RBC ') for credit facilities (the ' Credit Facilities ') that will support the Company's continued growth and operational flexibility, including working capital requirements and potential expansion opportunities. The Credit Facilities consist of: (i) a revolving demand facility in the amount of $1 million bearing interest at the Royal Bank Prime Rate + 1.25%; and (ii) a revolving term facility in the amount of $500,000 available by way of a series of variable rate term loans and fixed rate term loans with terms up to 72 months. The specific repayment terms of a drawdown under the revolving term facility will be agreed to between the Company and RBC at the time of drawdown. 'We are very pleased to have secured this credit facility with RBC,' said John Babic, President & CEO of Reeflex. 'This financing represents a vote of confidence in our business model, management team, and long-term strategic vision. It also enhances our ability to execute on our growth plans.' The Credit Facilities are secured by a General Security Agreement constituting a first ranking security interest in all of the property of Reeflex and a personal guarantee by an officer and director of the Company. The credit agreement includes standard financial reporting obligations and customary fees, including an annual renewal fee, arrangement fee, and monthly management fee. About Reeflex Reeflex is a public company delivering advanced engineering and manufacturing solutions across various industry sectors. Through our wholly-owned subsidiary, Coil Solutions Inc., we provide coil tubing injectors and downhole tools for the oil & gas sector. Our manufacturing division, Ranglar Manufacturing, specializes in custom-designed mobile equipment for a wide range of industrial applications. See and Reeflex Contact For further information, please contact: John Babic President, Chief Executive Officer and Director Email: Telephone: 780-909-4220 Cautionary Note Regarding Forward - Looking Information This press release contains 'forward-looking information' or 'forward-looking statements' within the meaning of Canadian securities legislation. All statements included herein, other than statements of historical fact, including statements included in the 'About Reeflex' section of this press release, are forward-looking. Generally, the forward-looking information and forward-looking statements can be identified by the use of forward-looking terminology such as 'anticipate', 'believes', 'estimates', 'expects', 'intends', 'may', 'should', 'will' or variations of such words or similar expressions. More particularly, and without limitation, this press release contains forward-looking information or forward-looking statements concerning the resumption of trading of the Reeflex Shares on the TSXV and Reeflex capitalizing on opportunities for growth in its industry. Reeflex cautions that all forward-looking information and forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, assumptions and expectations, many of which are beyond the control of Reeflex, including expectations and assumptions concerning Reeflex, as well as other risks and uncertainties, including those described in Reeflex's filings available on SEDAR+ at The reader is cautioned that assumptions used in the preparation of any forward-looking information or forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted as a result of numerous known and unknown risks, uncertainties and other factors, many of which are beyond the control of Reeflex. The reader is cautioned not to place undue reliance on any forward-looking information or forward-looking statements. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking information and forward-looking statements contained in this press release are expressly qualified by this cautionary statement. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and Reeflex does not undertake any obligation to update publicly or to revise any of the included forward-looking information or forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
